Common heartburn medicine being tested on COVID-19 patients in New York


A generic heartburn medicine is being tested on COVID-19 patients at Northwell Health hospitals in the New York City area, but don't rush to the drugstore, Dr. Kevin Tracey, the head of Northwell's Feinstein Institute for Medical Research, told CNN on Sunday. The 187 patients in the trial are either getting massive doses of famotidine, the active ingredient in Pepcid, or a saline placebo solution, and the first results won't be released for at least a few weeks. The trial started March 13, but it was kept under wraps in part to prevent a run on famotidine.
There is no real evidence that famotidine is effective at treating COVID-19, but the hope is that the drug could prevent the coronavirus from replicating by essentially preoccupying it, similar to how protease inhibitors stop HIV. Tracey said he got the idea to test the heartburn medicine from a colleague, Dr. Michael Callahan, who observed improvement among COVID-19 patients in China who were taking famotidine rather than a more expensive medicine to treat their heartburn. Famotidine was also near the top of a computer model's ranking of existing drugs that might work against the coronavirus, based on its genome.
If the drug proves effective, "it's generic, it's plentiful, and it's inexpensive," Tracey told CNN. But until then, "we have to remain skeptical," Dr. Carlos Del Rio at Emory University told ABC News. "In the early years of HIV, we tried a lot of stuff and we thought, 'Oh this is going to work' and nothing worked." That also appears to be the case with the malaria drug hydroxychloroquine, which all the Northwell test subjects are also taking, for now. Famotidine, at least, appears to be safe, said Dr. Stuart Ray at Johns Hopkins. "I think this sort of off-label repurposing is sensible with drugs for which we have a long safety record," he told ABC News. "And we really need a win."
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
The trial of Jair Bolsonaro, the 'Trump of the tropics'
The Explainer Brazil's former president will likely be found guilty of attempting military coup, despite US pressure and Trump allegiance
-
Telephobia: why young people are being taught how to make phone calls
In The Spotlight Young people are so scared of calls that they 'scream' when their phone rings
-
Crossword: September 2, 2025
The Week's daily crossword
-
New York court tosses Trump's $500M fraud fine
Speed Read A divided appeals court threw out a hefty penalty against President Trump for fraudulently inflating his wealth
-
Trump said to seek government stake in Intel
Speed Read The president and Intel CEO Lip-Bu Tan reportedly discussed the proposal at a recent meeting
-
US to take 15% cut of AI chip sales to China
Speed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China
-
NFL gets ESPN stake in deal with Disney
Speed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network
-
Samsung to make Tesla chips in $16.5B deal
Speed Read Tesla has signed a deal to get its next-generation chips from Samsung
-
FCC greenlights $8B Paramount-Skydance merger
Speed Read The Federal Communications Commission will allow Paramount to merge with the Hollywood studio Skydance
-
Tesla reports plummeting profits
Speed Read The company may soon face more problems with the expiration of federal electric vehicle tax credits
-
Dollar faces historic slump as stocks hit new high
Speed Read While stocks have recovered post-Trump tariffs, the dollar has weakened more than 10% this year